NCT03166397 2023-01-26
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
Phase 2 Recruiting
Clinical Trials
5 trialsNCT05385263 2022-05-26
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT03808480 2022-04-06
Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
National Cancer Center, Korea
Phase 2 Unknown
NCT03569696 2019-04-23
NivoM
Sheba Medical Center
Phase 2 Unknown
NCT02982486 2017-11-01
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
Assaf-Harofeh Medical Center
Phase 2 Unknown